The overlooked nutrition risk of Ozempic and WegovyThe overlooked nutrition risk of Ozempic and Wegovy
Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies. Popular weight-loss Read More
GLP-1 obesity drugs can complicate life for people with disordered eatingGLP-1 obesity drugs can complicate life for people with disordered eating
Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders. (Image credit: Edwin J. Torres for NPR) Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with eating disorders. (Image credit: Edwin Read More
GLP-1 obesity drugs can complicate life for people with disordered eatingGLP-1 obesity drugs can complicate life for people with disordered eating
Doctors, patients and researchers are at the very beginning of understanding how the new weight loss medicines interact with eating disorders. Doctors, patients and researchers are at the very beginning of understanding how the new weight loss medicines interact with eating disorders.
RNA molecule discovery could lead to potential new breast cancer therapyRNA molecule discovery could lead to potential new breast cancer therapy
QIMR Berghofer scientists have discovered a cancer-fighting RNA molecule that could hold the key to a new way of treating the most common form of breast cancer. The team are developing their findings into a potential RNA-based therapy for hormone receptor-positive (HR+) breast cancer, offering hope to women with advanced disease who are no longer responding to existing drugs.
More GLP-1 Drug Lawsuits; Military’s Rising Obesity Rates; Male Birth Control Soon?More GLP-1 Drug Lawsuits; Military’s Rising Obesity Rates; Male Birth Control Soon?
(MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with GLP-1 receptor agonists. (USA Today) Meanwhile, the U.K.’s Medicines and Healthcare Products Regulatory Agency… (MedPage Today) — More lawsuits are alleging that patients are not being sufficiently warned of certain severe injuries associated with Read More
Rethinking weight loss in the Ozempic era: Researchers urge a more holistic viewRethinking weight loss in the Ozempic era: Researchers urge a more holistic view
In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: “Can you believe we finally reached this moment, that we lived long enough to see this?” In the world of obesity research, the Read More
Novel antibody targets fat cell protein, offering new approach to treating metabolism-related liver cancerNovel antibody targets fat cell protein, offering new approach to treating metabolism-related liver cancer
Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become increasingly common in recent years. A research team from The Hong Kong Polytechnic University (PolyU) has identified a protein secreted by fat cells that promotes cancer growth and has successfully developed a novel antibody that neutralizes this protein, marking a significant breakthrough in impeding the progression of liver cancer. The research findings have been published in the Journal of Clinical Investigation.
STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competitionSTAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market. The Danish pharma giant said it expects sales to decrease in the range of 5% to 13% in 2026, more than the 3% decrease forecasted by analysts surveyed by Read More
NIH Grant Disruptions Slow Down Breast Cancer ResearchNIH Grant Disruptions Slow Down Breast Cancer Research
(MedPage Today) — Inside a cancer research laboratory on the campus of Harvard Medical School, two dozen small jars with pink plastic lids sat on a metal counter. Inside these humble-looking jars is the core of the current multiyear research project…
GLP-1 drugs tied to lower-calorie, lower-sugar food purchasesGLP-1 drugs tied to lower-calorie, lower-sugar food purchases
Researchers at Steno Diabetes Center Copenhagen reported that starting a GLP-1 receptor agonist (GLP-1RA) coincided with slightly healthier supermarket purchases. Grocery purchases from GLP-1RA users in Denmark contained modestly fewer calories and sugars and slightly more protein per 100 g of food after treatment began than before. Researchers at Steno Diabetes Center Copenhagen reported that Read More